Stock data
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM) reported revenue of US$638.50M and net income of -US$183.17M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$638.50M | — | -US$166.76M | -US$183.17M | — |
| 2024 | US$385.69M | — | -US$280.56M | -US$287.22M | — |
| 2023 | US$270.60M | — | -US$231.82M | -US$239.24M | — |
| 2022 | US$50.04M | — | -US$179.80M | -US$187.13M | — |
| 2021 | — | — | -US$124.71M | -US$130.40M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$218.38M | -US$51.31M | — |
| 2026-03-31 | US$191.20M | -US$64.54M | — |
| 2025-12-31 | US$196.00M | -US$28.56M | — |
| 2025-09-30 | US$170.99M | -US$47.23M | — |
| 2025-06-30 | US$150.04M | -US$47.97M | — |
| 2025-03-31 | US$121.46M | -US$59.41M | — |
| 2024-12-31 | US$118.77M | -US$74.91M | — |
| 2024-09-30 | US$104.76M | -US$64.60M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.